{"transactions":[{"id":1297711,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":83973,"kind":"person","name":"Werner Milton H.","position":1,"cik":"0001827621","reported_name":"Werner Milton H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-22T21:05:06.000Z","date":"2025-01-21","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":45000,"derivative":{"exercise_price":1.26,"expiration_date":"2031-04-01","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0000950170-25-007741","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025007741/ownership.xml","form_type":"4"}},{"id":1297710,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":83973,"kind":"person","name":"Werner Milton H.","position":1,"cik":"0001827621","reported_name":"Werner Milton H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-22T21:05:06.000Z","date":"2025-01-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":2.16,"expiration_date":"2031-04-01","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0000950170-25-007741","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025007741/ownership.xml","form_type":"4"}},{"id":1297709,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":83973,"kind":"person","name":"Werner Milton H.","position":1,"cik":"0001827621","reported_name":"Werner Milton H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-22T21:05:06.000Z","date":"2025-01-21","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"shares","element":"transactionShares","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."}],"balance_after":35000,"derivative":{"exercise_price":1.26,"expiration_date":"2030-03-01","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0000950170-25-007741","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025007741/ownership.xml","form_type":"4"}},{"id":1297708,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":83973,"kind":"person","name":"Werner Milton H.","position":1,"cik":"0001827621","reported_name":"Werner Milton H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-22T21:05:06.000Z","date":"2025-01-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"shares","element":"transactionShares","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."}],"balance_after":0,"derivative":{"exercise_price":4.44,"expiration_date":"2030-03-01","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0000950170-25-007741","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025007741/ownership.xml","form_type":"4"}},{"id":1297707,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":83973,"kind":"person","name":"Werner Milton H.","position":1,"cik":"0001827621","reported_name":"Werner Milton H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-22T21:05:06.000Z","date":"2025-01-21","kind":"grant","planned":false,"acquired":true,"shares":20834,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"shares","element":"transactionShares","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."}],"balance_after":20834,"derivative":{"exercise_price":1.26,"expiration_date":"2029-03-07","underlying":"Common Stock","underlying_shares":20834},"source":{"system":"sec-edgar","filing":"0000950170-25-007741","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025007741/ownership.xml","form_type":"4"}},{"id":1297706,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":83973,"kind":"person","name":"Werner Milton H.","position":1,"cik":"0001827621","reported_name":"Werner Milton H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-22T21:05:06.000Z","date":"2025-01-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20834,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"shares","element":"transactionShares","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."}],"balance_after":0,"derivative":{"exercise_price":6.42,"expiration_date":"2029-03-07","underlying":"Common Stock","underlying_shares":20834},"source":{"system":"sec-edgar","filing":"0000950170-25-007741","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025007741/ownership.xml","form_type":"4"}},{"id":1297705,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":83973,"kind":"person","name":"Werner Milton H.","position":1,"cik":"0001827621","reported_name":"Werner Milton H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-22T21:05:06.000Z","date":"2025-01-21","kind":"grant","planned":false,"acquired":true,"shares":16667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"shares","element":"transactionShares","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."}],"balance_after":16667,"derivative":{"exercise_price":1.26,"expiration_date":"2030-12-22","underlying":"Common Stock","underlying_shares":16667},"source":{"system":"sec-edgar","filing":"0000950170-25-007741","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025007741/ownership.xml","form_type":"4"}},{"id":1297704,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":83973,"kind":"person","name":"Werner Milton H.","position":1,"cik":"0001827621","reported_name":"Werner Milton H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-22T21:05:06.000Z","date":"2025-01-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"shares","element":"transactionShares","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."}],"balance_after":0,"derivative":{"exercise_price":60,"expiration_date":"2030-12-22","underlying":"Common Stock","underlying_shares":16667},"source":{"system":"sec-edgar","filing":"0000950170-25-007741","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025007741/ownership.xml","form_type":"4"}},{"id":1297703,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":83973,"kind":"person","name":"Werner Milton H.","position":1,"cik":"0001827621","reported_name":"Werner Milton H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-22T21:05:06.000Z","date":"2025-01-21","kind":"grant","planned":false,"acquired":true,"shares":3643,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"shares","element":"transactionShares","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."}],"balance_after":3643,"derivative":{"exercise_price":1.26,"expiration_date":"2029-11-01","underlying":"Common Stock","underlying_shares":3643},"source":{"system":"sec-edgar","filing":"0000950170-25-007741","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025007741/ownership.xml","form_type":"4"}},{"id":1297702,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":83973,"kind":"person","name":"Werner Milton H.","position":1,"cik":"0001827621","reported_name":"Werner Milton H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-22T21:05:06.000Z","date":"2025-01-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3643,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"shares","element":"transactionShares","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."}],"balance_after":0,"derivative":{"exercise_price":33.43,"expiration_date":"2029-11-01","underlying":"Common Stock","underlying_shares":3643},"source":{"system":"sec-edgar","filing":"0000950170-25-007741","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025007741/ownership.xml","form_type":"4"}},{"id":1297701,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":83973,"kind":"person","name":"Werner Milton H.","position":1,"cik":"0001827621","reported_name":"Werner Milton H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-22T21:05:06.000Z","date":"2025-01-21","kind":"grant","planned":false,"acquired":true,"shares":3643,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"shares","element":"transactionShares","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."}],"balance_after":3643,"derivative":{"exercise_price":1.26,"expiration_date":"2028-11-01","underlying":"Common Stock","underlying_shares":3643},"source":{"system":"sec-edgar","filing":"0000950170-25-007741","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025007741/ownership.xml","form_type":"4"}},{"id":1297700,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":83973,"kind":"person","name":"Werner Milton H.","position":1,"cik":"0001827621","reported_name":"Werner Milton H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-22T21:05:06.000Z","date":"2025-01-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3643,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"shares","element":"transactionShares","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."}],"balance_after":0,"derivative":{"exercise_price":28.76,"expiration_date":"2028-11-01","underlying":"Common Stock","underlying_shares":3643},"source":{"system":"sec-edgar","filing":"0000950170-25-007741","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025007741/ownership.xml","form_type":"4"}},{"id":1297699,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":83973,"kind":"person","name":"Werner Milton H.","position":1,"cik":"0001827621","reported_name":"Werner Milton H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-22T21:05:06.000Z","date":"2025-01-21","kind":"grant","planned":false,"acquired":true,"shares":3643,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"shares","element":"transactionShares","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."}],"balance_after":3643,"derivative":{"exercise_price":1.26,"expiration_date":"2027-11-01","underlying":"Common Stock","underlying_shares":3643},"source":{"system":"sec-edgar","filing":"0000950170-25-007741","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025007741/ownership.xml","form_type":"4"}},{"id":1297698,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":83973,"kind":"person","name":"Werner Milton H.","position":1,"cik":"0001827621","reported_name":"Werner Milton H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-22T21:05:06.000Z","date":"2025-01-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3643,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"shares","element":"transactionShares","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."}],"balance_after":0,"derivative":{"exercise_price":13.86,"expiration_date":"2027-11-01","underlying":"Common Stock","underlying_shares":3643},"source":{"system":"sec-edgar","filing":"0000950170-25-007741","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025007741/ownership.xml","form_type":"4"}},{"id":1297697,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":83973,"kind":"person","name":"Werner Milton H.","position":1,"cik":"0001827621","reported_name":"Werner Milton H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-22T21:05:06.000Z","date":"2025-01-21","kind":"grant","planned":false,"acquired":true,"shares":3643,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"shares","element":"transactionShares","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."}],"balance_after":3643,"derivative":{"exercise_price":1.26,"expiration_date":"2026-11-01","underlying":"Common Stock","underlying_shares":3643},"source":{"system":"sec-edgar","filing":"0000950170-25-007741","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025007741/ownership.xml","form_type":"4"}},{"id":1297696,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":83973,"kind":"person","name":"Werner Milton H.","position":1,"cik":"0001827621","reported_name":"Werner Milton H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-22T21:05:06.000Z","date":"2025-01-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3643,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"shares","element":"transactionShares","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."}],"balance_after":0,"derivative":{"exercise_price":13.86,"expiration_date":"2026-11-01","underlying":"Common Stock","underlying_shares":3643},"source":{"system":"sec-edgar","filing":"0000950170-25-007741","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025007741/ownership.xml","form_type":"4"}},{"id":1297695,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":83973,"kind":"person","name":"Werner Milton H.","position":1,"cik":"0001827621","reported_name":"Werner Milton H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-22T21:05:06.000Z","date":"2025-01-21","kind":"grant","planned":false,"acquired":true,"shares":3643,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"shares","element":"transactionShares","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."}],"balance_after":3643,"derivative":{"exercise_price":1.26,"expiration_date":"2025-11-01","underlying":"Common Stock","underlying_shares":3643},"source":{"system":"sec-edgar","filing":"0000950170-25-007741","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025007741/ownership.xml","form_type":"4"}},{"id":1297694,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":83973,"kind":"person","name":"Werner Milton H.","position":1,"cik":"0001827621","reported_name":"Werner Milton H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-22T21:05:06.000Z","date":"2025-01-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3643,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"shares","element":"transactionShares","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."}],"balance_after":0,"derivative":{"exercise_price":13.86,"expiration_date":"2025-11-01","underlying":"Common Stock","underlying_shares":3643},"source":{"system":"sec-edgar","filing":"0000950170-25-007741","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025007741/ownership.xml","form_type":"4"}},{"id":1308143,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":83973,"kind":"person","name":"Werner Milton H.","position":1,"cik":"0001827621","reported_name":"Werner Milton H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-07T23:47:23.000Z","date":"2025-01-03","kind":"grant","planned":false,"acquired":true,"shares":4059744,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options will vest and become exercisable upon the expiration of the exercise period of the Issuer's Series B-1 Warrants in an amount proportional to the actual number of Series B-1 Warrants exercised, subject to the Reporting Person's continuous service to the Issuer through such date. Any options that do not become vested shall be automatically forfeited without consideration in respect thereof."}],"balance_after":4059744,"derivative":{"exercise_price":1.58,"expiration_date":"2035-01-03","underlying":"Common Stock","underlying_shares":4059744},"source":{"system":"sec-edgar","filing":"0000950170-25-003132","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025003132/ownership.xml","form_type":"4"}},{"id":1308142,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":83973,"kind":"person","name":"Werner Milton H.","position":1,"cik":"0001827621","reported_name":"Werner Milton H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-07T23:47:23.000Z","date":"2025-01-03","kind":"grant","planned":false,"acquired":true,"shares":2207671,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options will vest and become exercisable upon the expiration of the exercise period of the Issuer's Series A-1 Warrants in an amount proportional to the actual number of Series A-1 Warrants exercised, subject to the Reporting Person's continuous service to the Issuer through such date. Any options that do not become vested shall be automatically forfeited without consideration in respect thereof."}],"balance_after":2207671,"derivative":{"exercise_price":1.45,"expiration_date":"2035-01-03","underlying":"Common Stock","underlying_shares":2207671},"source":{"system":"sec-edgar","filing":"0000950170-25-003132","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025003132/ownership.xml","form_type":"4"}},{"id":1308141,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":83973,"kind":"person","name":"Werner Milton H.","position":1,"cik":"0001827621","reported_name":"Werner Milton H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-07T23:47:23.000Z","date":"2025-01-03","kind":"grant","planned":false,"acquired":true,"shares":5315056,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vested and became exercisable on October 9, 2024."}],"balance_after":5315056,"derivative":{"exercise_price":1.26,"expiration_date":"2035-01-03","underlying":"Common Stock","underlying_shares":5315056},"source":{"system":"sec-edgar","filing":"0000950170-25-003132","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025003132/ownership.xml","form_type":"4"}},{"id":1549855,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":83973,"kind":"person","name":"Werner Milton H.","position":1,"cik":"0001827621","reported_name":"Werner Milton H.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2024-04-03T20:47:23.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the options will vest and become exercisable on April 1, 2025, and the remaining portion will vest and become exercisable in 24 equal monthly installments commencing on the first day of April 2025, subject to continued employment through each such vesting date."}],"balance_after":45000,"derivative":{"exercise_price":2.16,"expiration_date":"2031-04-01","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0000950170-24-041191","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017024041191/ownership.xml","form_type":"4"}},{"id":1974021,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":83973,"kind":"person","name":"Werner Milton H.","position":1,"cik":"0001827621","reported_name":"Werner Milton H.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-03-03T22:00:33.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":210000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the options will vest and become exercisable on 3/1/2024, and the remaining portion will vest and become exercisable in 24 equal monthly installments commencing on the first day of April 2024, subject to continued employment through each such vesting date."}],"balance_after":210000,"derivative":{"exercise_price":0.74,"expiration_date":"2030-03-01","underlying":"Common Stock","underlying_shares":210000},"source":{"system":"sec-edgar","filing":"0000899243-23-007010","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000089924323007010/doc4.xml","form_type":"4"}},{"id":2184359,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":83973,"kind":"person","name":"Werner Milton H.","position":1,"cik":"0001827621","reported_name":"Werner Milton H.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-08-16T20:25:46.000Z","date":"2022-08-16","kind":"purchase","acquired":true,"shares":5000,"price":0.8,"value":4000.0,"ownership":{"direct":true},"balance_after":5335433,"source":{"system":"sec-edgar","filing":"0000899243-22-028794","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000089924322028794/doc4.xml","form_type":"4"}},{"id":2251513,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":83973,"kind":"person","name":"Werner Milton H.","position":1,"cik":"0001827621","reported_name":"Werner Milton H.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-05-31T14:16:50.000Z","date":"2022-05-27","kind":"purchase","acquired":true,"shares":5000,"price":0.976,"value":4880.0,"ownership":{"direct":true},"balance_after":5330433,"source":{"system":"sec-edgar","filing":"0000899243-22-020094","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000089924322020094/doc4.xml","form_type":"4"}},{"id":2260171,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":83973,"kind":"person","name":"Werner Milton H.","position":1,"cik":"0001827621","reported_name":"Werner Milton H.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-05-23T20:57:53.000Z","date":"2022-05-20","kind":"purchase","acquired":true,"shares":10000,"price":0.6,"value":6000.0,"ownership":{"direct":true},"balance_after":5325433,"source":{"system":"sec-edgar","filing":"0000899243-22-019229","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000089924322019229/doc4.xml","form_type":"4"}},{"id":2323193,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":83973,"kind":"person","name":"Werner Milton H.","position":1,"cik":"0001827621","reported_name":"Werner Milton H.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-03-21T20:05:11.000Z","date":"2022-03-07","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the options will vest and become exercisable on 3/7/2023, and the remaining portion will vest and become exercisable in 24 equal monthly installments commencing on the first day of April 2023, subject to continued employment through each such vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The original Form 4, filed on March 9, 2022, is being amended by this Form 4 amendment solely to correct an error that misreported that the 24 equal monthly installments mentioned in footnote 1 would begin on the first day of April 2024, rather than the first day of April 2023 as intended."}],"balance_after":125000,"derivative":{"exercise_price":1.07,"expiration_date":"2029-03-07","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0000899243-22-011698","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000089924322011698/doc4.xml","form_type":"4"}},{"id":2342059,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":83973,"kind":"person","name":"Werner Milton H.","position":1,"cik":"0001827621","reported_name":"Werner Milton H.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-03-10T01:21:44.000Z","date":"2022-03-07","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the options will vest and become exercisable on 3/7/2023, and the remaining portion will vest and become exercisable in 24 equal\nmonthly installments commencing on the first day of April 2024, subject to continued employment through each such\nvesting date."}],"balance_after":125000,"derivative":{"exercise_price":1.07,"expiration_date":"2029-03-07","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0000899243-22-010332","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000089924322010332/doc4.xml","form_type":"4"}},{"id":2449627,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":83973,"kind":"person","name":"Werner Milton H.","position":1,"cik":"0001827621","reported_name":"Werner Milton H.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-01-05T02:25:42.000Z","date":"2022-01-03","kind":"exercise","acquired":false,"shares":21853,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vested in twelve equal monthly installments beginning on March 1, 2015."}],"balance_after":0,"derivative":{"exercise_price":2.02,"expiration_date":"2025-03-01","underlying":"Common Stock","underlying_shares":21853},"source":{"system":"sec-edgar","filing":"0001104659-22-001168","document":"tm221641d1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000110465922001168/tm221641d1_4.xml","form_type":"4"}},{"id":2449626,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":83973,"kind":"person","name":"Werner Milton H.","position":1,"cik":"0001827621","reported_name":"Werner Milton H.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-01-05T02:25:42.000Z","date":"2022-01-03","kind":"exercise","acquired":true,"shares":21853,"price":2.02,"value":44143.06,"ownership":{"direct":true},"balance_after":5315433,"source":{"system":"sec-edgar","filing":"0001104659-22-001168","document":"tm221641d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000110465922001168/tm221641d1_4.xml","form_type":"4"}},{"id":2503023,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":83973,"kind":"person","name":"Werner Milton H.","position":1,"cik":"0001827621","reported_name":"Werner Milton H.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-11-19T13:13:32.000Z","date":"2021-11-17","kind":"purchase","acquired":true,"shares":400,"price":1.93,"value":772.0,"ownership":{"direct":false,"nature":"Domestic Partner"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."}],"balance_after":23589,"source":{"system":"sec-edgar","filing":"0001104659-21-141628","document":"tm2133483d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000110465921141628/tm2133483d1_4.xml","form_type":"4"}},{"id":2503022,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":83973,"kind":"person","name":"Werner Milton H.","position":1,"cik":"0001827621","reported_name":"Werner Milton H.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-11-19T13:13:32.000Z","date":"2021-11-17","kind":"purchase","acquired":true,"shares":1334,"price":1.94,"value":2587.96,"ownership":{"direct":false,"nature":"Domestic Partner"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."}],"balance_after":23589,"source":{"system":"sec-edgar","filing":"0001104659-21-141628","document":"tm2133483d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000110465921141628/tm2133483d1_4.xml","form_type":"4"}},{"id":2503021,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":83973,"kind":"person","name":"Werner Milton H.","position":1,"cik":"0001827621","reported_name":"Werner Milton H.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-11-19T13:13:32.000Z","date":"2021-11-17","kind":"purchase","acquired":true,"shares":3186,"price":1.96,"value":6244.56,"ownership":{"direct":false,"nature":"Domestic Partner"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."}],"balance_after":23589,"source":{"system":"sec-edgar","filing":"0001104659-21-141628","document":"tm2133483d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000110465921141628/tm2133483d1_4.xml","form_type":"4"}},{"id":2503020,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":83973,"kind":"person","name":"Werner Milton H.","position":1,"cik":"0001827621","reported_name":"Werner Milton H.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-11-19T13:13:32.000Z","date":"2021-11-17","kind":"purchase","acquired":true,"shares":1100,"price":1.97,"value":2167.0,"ownership":{"direct":false,"nature":"Domestic Partner"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."}],"balance_after":23589,"source":{"system":"sec-edgar","filing":"0001104659-21-141628","document":"tm2133483d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000110465921141628/tm2133483d1_4.xml","form_type":"4"}},{"id":2503019,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":83973,"kind":"person","name":"Werner Milton H.","position":1,"cik":"0001827621","reported_name":"Werner Milton H.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-11-19T13:13:32.000Z","date":"2021-11-17","kind":"purchase","acquired":true,"shares":17569,"price":1.98,"value":34786.62,"ownership":{"direct":false,"nature":"Domestic Partner"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."}],"balance_after":23589,"source":{"system":"sec-edgar","filing":"0001104659-21-141628","document":"tm2133483d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000110465921141628/tm2133483d1_4.xml","form_type":"4"}},{"id":2596281,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":83973,"kind":"person","name":"Werner Milton H.","position":1,"cik":"0001827621","reported_name":"Werner Milton H.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-08-19T11:46:28.000Z","date":"2021-08-17","kind":"exercise","acquired":false,"shares":21853,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vested in twelve equal monthly installments beginning on June 1, 2013."}],"balance_after":0,"derivative":{"exercise_price":2.02,"expiration_date":"2023-06-01","underlying":"Common Stock","underlying_shares":21853},"source":{"system":"sec-edgar","filing":"0000899243-21-033598","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000089924321033598/doc4.xml","form_type":"4"}},{"id":2596280,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":83973,"kind":"person","name":"Werner Milton H.","position":1,"cik":"0001827621","reported_name":"Werner Milton H.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-08-19T11:46:28.000Z","date":"2021-08-17","kind":"exercise","acquired":true,"shares":21853,"price":2.02,"value":44143.06,"ownership":{"direct":true},"balance_after":5293580,"source":{"system":"sec-edgar","filing":"0000899243-21-033598","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000089924321033598/doc4.xml","form_type":"4"}},{"id":2708323,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":83973,"kind":"person","name":"Werner Milton H.","position":1,"cik":"0001827621","reported_name":"Werner Milton H.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-05-18T21:46:17.000Z","date":"2021-05-14","kind":"exercise","acquired":false,"shares":43707,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0.38,"exercise_date":"2011-06-01","expiration_date":"2021-06-01","underlying":"Common Stock","underlying_shares":43707},"source":{"system":"sec-edgar","filing":"0000899243-21-019788","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000089924321019788/doc4.xml","form_type":"4"}},{"id":2708322,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":83973,"kind":"person","name":"Werner Milton H.","position":1,"cik":"0001827621","reported_name":"Werner Milton H.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-05-18T21:46:17.000Z","date":"2021-05-14","kind":"tax_withholding","acquired":false,"shares":16918,"price":4.59,"value":77653.62,"ownership":{"direct":true},"balance_after":5271727,"source":{"system":"sec-edgar","filing":"0000899243-21-019788","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000089924321019788/doc4.xml","form_type":"4"}},{"id":2708321,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":83973,"kind":"person","name":"Werner Milton H.","position":1,"cik":"0001827621","reported_name":"Werner Milton H.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-05-18T21:46:17.000Z","date":"2021-05-14","kind":"exercise","acquired":true,"shares":43707,"price":0.38,"value":16608.66,"ownership":{"direct":true},"balance_after":5288645,"source":{"system":"sec-edgar","filing":"0000899243-21-019788","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000089924321019788/doc4.xml","form_type":"4"}},{"id":2930277,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":83973,"kind":"person","name":"Werner Milton H.","position":1,"cik":"0001827621","reported_name":"Werner Milton H.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2020-12-30T02:52:38.000Z","date":"2020-12-22","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the option will vest and become exercisable on 12/22/2021, and the remaining portion will vest and become exercisable in 24 equal monthly installments commencing on the first day of the month beginning January 1, 2022."}],"balance_after":100000,"derivative":{"exercise_price":10,"expiration_date":"2030-12-22","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001104659-20-140308","document":"tm2039455d2_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000110465920140308/tm2039455d2_form4.xml","form_type":"4"}}]}